Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Cash & Equivalents (2016 - 2025)

Integra Lifesciences Holdings' Cash & Equivalents history spans 17 years, with the latest figure at $235.0 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 4.6% year-over-year to $235.0 million; the TTM value through Dec 2025 reached $235.0 million, down 4.6%, while the annual FY2025 figure was $235.0 million, 4.6% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $235.0 million at Integra Lifesciences Holdings, up from $232.2 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $591.9 million in Q1 2024 and bottomed at $215.2 million in Q3 2024.
  • The 5-year median for Cash & Equivalents is $308.3 million (2023), against an average of $353.4 million.
  • The largest annual shift saw Cash & Equivalents soared 92.57% in 2024 before it tumbled 59.6% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $513.4 million in 2021, then rose by 7.61% to $552.5 million in 2022, then crashed by 49.97% to $276.4 million in 2023, then fell by 10.86% to $246.4 million in 2024, then dropped by 4.6% to $235.0 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Cash & Equivalents are $235.0 million (Q4 2025), $232.2 million (Q3 2025), and $217.9 million (Q2 2025).